Codiak BioSciences, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-03-29: Form 8-K; Period of report 2023-03-27; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2023-03-27: Form 8-K; Period of report 2023-03-23; Description 1.03 Bankruptcy or Receivership; 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 1.03.
- 2022-11-03: Form 8-K; Period of report 2022-11-03; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2022-09-14: Form 8-K; Period of report 2022-09-12; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2023-03-29 | 8-K | 2023-03-27 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 As previously reported, on March 27, 2023, Codiak BioSciences, Inc. (the “Company”) filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the “Filing”), thereby commencing a Chapter 11 case for the Company (Case No. 23-10350). | d470562d8k.htm |
| 2023-03-27 | 8-K | 2023-03-23 | 1.03 Bankruptcy or Receivership; 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.03 On March 27, 2023, Codiak BioSciences, Inc. (the “Company”) filed a voluntary petition (the “Bankruptcy Petition”) for relief under Chapter 11 of Title 11 (“Chapter 11”) of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), thereby commencing a Chapter 11 case for the Company (Case No. 23-10350). 2.05 On March 23, 2023, the board of directors (the “Board”) of Codiak BioSciences, Inc. approved a restructuring of operations and corresponding reduction in workforce, designed to reduce costs and reallocate resources while maintaining the personnel needed to support the Company’s key programs and refocused pipeline, including the wind down of the Company’s clinical trial for exoASO™-STAT6, while the Company explores strategic alternatives (the “Restructuring”). 5.02 In connection with the Restructuring discussed in Item 2.05 above, the following members of the Company’s executive team will be leaving the Company to pursue new opportunities: (i) Douglas E. Williams, Ph.D., President and Chief Executive Officer, (ii) Linda C. Bain, Chief Financial Officer and Treasurer, (iii) David Mauro, M.D., Ph.D., Chief Medical Officer, (iv) Sriram Sathyanarayanan, Ph.D., Chief Scientific Officer, (v) Yalonda Howze, Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary, and (iv) Nicole Barna, Senior Vice President, Human Resources. 8.01 On March 27, 2023, the Company issued a press release announcing its Bankruptcy Petition and related matters. | d467120d8k.htm |
| 2022-11-03 | 8-K | 2022-11-03 | 2.02 Results of Operations and Financial Condition | 2.02 On November 3, 2022, Codiak BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2022. | d407412d8k.htm |
| 2022-09-14 | 8-K | 2022-09-12 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On September 12, 2022, the Company issued press releases announcing the launch and pricing of the Offering, copies of which are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and incorporated herein by reference. | d297611d8k.htm |
| 2022-08-30 | 8-K | 2022-08-25 | 2.05 Costs Associated with Exit or Disposal Activities; 8.01 Other Events | 2.05 On August 25, 2022, the board of directors (the “Board”) of Codiak BioSciences, Inc. (the “Company”) approved a reprioritization of the Company’s clinical and research initiatives and a restructuring of operations and corresponding reduction in workforce, designed to reduce costs and reallocate resources while maintaining the personnel needed to support the Company’s key programs and refocused pipeline (the “Restructuring”). 8.01 On August 30, 2022, the Company issued a press release announcing the Restructuring. | d401300d8k.htm |
| 2022-08-04 | 8-K | 2022-08-04 | 2.02 Results of Operations and Financial Condition | 2.02 On August 4, 2022, Codiak BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2022. | d535188d8k.htm |
| 2022-06-30 | 8-K | 2022-06-30 | 7.01 Regulation FD Disclosure | 7.01 On June 30, 2022, Codiak BioSciences, Inc. (the “Company”) issued a press release announcing platform-validating clinical data from the Phase 1 trials of exoSTING TM and exoIL-12™ and plans to advance both candidates into Phase 2 trials. | d265935d8k.htm |
| 2022-06-29 | 8-K | 2022-06-29 | 8.01 Other Events | 8.01 On June 29, 2022, Codiak BioSciences, Inc. (the “Company”) issued a press release announcing the initiation of patient dosing in its Phase 1 clinical trial of exoASO-STAT6, an engineered exosome precision medicine candidate designed to selectively deliver antisense oligonucleotides to disrupt STAT6 signaling in tumor associated macrophages and induce an anti-tumor immune response. | d374770d8k.htm |
| 2022-06-21 | 8-K | 2022-06-17 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 – Submission of Matters to a Vote of Security Holders. | d352729d8k.htm |
| 2022-05-05 | 8-K | 2022-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2022, Codiak BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2022. | d274549d8k.htm |
| 2022-03-10 | 8-K | 2022-03-10 | 2.02 Results of Operations and Financial Condition | 2.02 On March 10, 2022, Codiak BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2021 and describing recent operational progress. | d323220d8k.htm |
| 2021-11-30 | 8-K | 2021-11-30 | 7.01 Regulation FD Disclosure | 7.01 On November 30, 2021, Codiak BioSciences, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug Application for exoASO-STAT6. | d221781d8k.htm |
| 2021-11-17 | 8-K | 2021-11-16 | 7.01 Regulation FD Disclosure | 7.01 On November 16, 2021, Codiak BioSciences, Inc. (the “Company”) issued a press release announcing initial data for exoSTING, a novel engineered exosome therapeutic candidate currently being investigated in a Phase 1/2 clinical trial as a single agent for the treatment of multiple solid tumors. | d253552d8k.htm |
| 2021-11-16 | 8-K | 2021-11-15 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d250299d8k.htm |
| 2021-11-04 | 8-K | 2021-11-04 | 1.01 Entry into a Material Definitive Agreement | 1.01 On November 4, 2021, Codiak BioSciences, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Jefferies LLC (“Jefferies”) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $100.0 million (the “Placement Shares”) through Jefferies as its sales agent. | d254853d8k.htm |
| 2021-11-04 | 8-K | 2021-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2021, Codiak BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2021. | d241723d8k.htm |
| 2021-11-02 | 8-K | 2021-11-01 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d193591d8k.htm |
| 2021-10-07 | 8-K | 2021-10-01 | 1.02 Termination of a Material Definitive Agreement | 1.02 On October 1, 2021, Sarepta Therapeutics, Inc. (“Sarepta”) notified Codiak BioSciences, Inc. (the “Company”) that it was terminating early the two-year Research License and Option Agreement, effective June 17, 2020, between Sarepta and the Company (the “Agreement”). | d77768d8k.htm |
| 2021-09-21 | 8-K | 2021-09-16 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information provided in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. | d164714d8k.htm |
| 2021-08-18 | 8-K | 2021-08-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On August 16, 2021, the Board of Directors (the “Board”) of Codiak BioSciences, Inc., a Delaware corporation (the “Company”), appointed Lini Pandite, MBChB, MBA to the Board, effective August 16, 2021. | d197111d8k.htm |
| 2021-08-05 | 8-K | 2021-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2021, Codiak BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2021. | d813875d8k.htm |
| 2021-07-06 | 8-K | 2021-07-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 (b) On July 6, 2021, Benny Sorensen, M.D., Ph.D. resigned from his position as the Senior Vice President, Strategic Projects of Codiak BioSciences, Inc. (the “Company”) to become CEO of a privately held biotech company focused on rare bleeding and thrombosis disorders. | d164212d8k.htm |
| 2021-06-23 | 8-K | 2021-06-18 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 – Submission of Matters to a Vote of Security Holders. | d182645d8k.htm |
| 2021-05-20 | 8-K | 2021-05-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Anne-Virginie Eggimann, M.Sc. | d166923d8k.htm |
| 2021-05-10 | 8-K | 2021-05-10 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 10, 2021, Codiak BioSciences, Inc. (the “Company”) announced the appointment of Jennifer Wheler, M.D., as Chief Medical Officer, effective as of May 10, 2021 (the “Effective Date”). | d467786d8k.htm |
| 2021-05-06 | 8-K | 2021-05-06 | 2.02 Results of Operations and Financial Condition | 2.02 On May 6, 2021, Codiak BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2021. | d32775d8k.htm |
| 2021-04-08 | 8-K | 2021-04-02 | 7.01 Regulation FD Disclosure | 7.01 On April 2, 2021, Codiak BioSciences, Inc. (“Codiak”) and Jazz Pharmaceuticals Ireland Limited (“Jazz”) mutually agreed to discontinue their work on exoASO™-STAT3, one of five oncogene targets subject to the Collaboration and License Agreement by and between Codiak and Jazz, dated as of January 2, 2019 (the “Collaboration Agreement”), a copy of which is filed as Exhibit 10.14 to Codiak’s Registration Statement on Form S-1, as amended (File No. 333-248692), filed on October 7, 2020. | d171635d8k.htm |
| 2021-03-26 | 8-K | 2021-03-24 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 24, 2021, Briggs Morrison, M.D. resigned from the Board of Directors (the “Board”) of Codiak BioSciences, Inc. (the “Company”), and all committees thereof. | d160560d8k.htm |
| 2021-03-17 | 8-K | 2021-03-17 | 2.02 Results of Operations and Financial Condition | 2.02 On March 17, 2021, Codiak BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2020 and providing a business update. | d118984d8k.htm |
| 2021-03-08 | 8-K | 2021-03-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 5, 2021, Ajay Verma, M.D., Ph.D., the Executive Vice President, Research and Experimental Medicine of Codiak BioSciences, Inc. (the “Company”), separated from the Company, effective as of March 5, 2021. | d348747d8k.htm |
| 2021-02-04 | 8-K | 2021-02-04 | 8.01 Other Events | 8.01 On February 4, 2021, Codiak BioSciences, Inc. (the “Company”) issued a press release announcing pharmacodynamic (PD) activity results from the healthy volunteer portion of its randomized, placebo-controlled, double-blind Phase 1 trial of the Company’s clinical candidate, exoIL-12. | d75669d8k.htm |
| 2021-01-26 | 8-K | 2021-01-20 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. | d118801d8k.htm |
| 2020-12-30 | 8-K | 2020-12-30 | 8.01 Other Events | 8.01 On December 30, 2020, Codiak BioSciences, Inc. (the “Company”) issued a press release announcing results from the initial part of its Phase 1 clinical trial of exoIL-12. | d64502d8k.htm |
| 2020-11-20 | 8-K | 2020-11-19 | 2.02 Results of Operations and Financial Condition | 2.02 On November 19, 2020, Codiak BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2020. | d45892d8k.htm |